South Dakota Investment Council Takes Position in Repligen Corporation $RGEN

South Dakota Investment Council acquired a new stake in Repligen Corporation (NASDAQ:RGEN) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,900 shares of the biotechnology company’s stock, valued at approximately $236,000.

Other institutional investors also recently modified their holdings of the company. Twin Tree Management LP bought a new stake in shares of Repligen in the 1st quarter valued at $29,000. Hantz Financial Services Inc. boosted its stake in Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares in the last quarter. Signaturefd LLC boosted its stake in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 128 shares in the last quarter. Center for Financial Planning Inc. boosted its stake in Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 126 shares in the last quarter. Finally, AlphaQuest LLC bought a new position in Repligen during the second quarter worth $104,000. 97.64% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company’s stock.

Repligen Stock Down 2.2%

Repligen stock opened at $146.93 on Wednesday. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The firm has a market capitalization of $8.27 billion, a price-to-earnings ratio of 7,350.18, a price-to-earnings-growth ratio of 3.32 and a beta of 1.08. The firm’s fifty day moving average price is $136.52 and its two-hundred day moving average price is $129.15. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm had revenue of $188.80 million for the quarter, compared to analyst estimates of $181.23 million. During the same period last year, the firm earned $0.43 earnings per share. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several research analyst reports. Canaccord Genuity Group increased their target price on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday, October 29th. Stephens raised shares of Repligen to an “overweight” rating and set a $160.00 target price on the stock in a research note on Tuesday, July 22nd. Evercore ISI increased their target price on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Hsbc Global Res raised shares of Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $173.85.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.